STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost radiation for head and neck cancer
Disease control Recruiting nowThis early-phase trial tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. About 46 adults with certain types of head and neck cancer will receive ipatasertib alongside …
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 22:36 UTC
-
New combo therapy aims to shrink tumors in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biomarkers in the tumor can predict who responds best. About…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New combo therapy aims to improve survival in recurrent head and neck cancer
Disease control Recruiting nowThis study tests whether adding chemotherapy or a chemo-immunotherapy combination before salvage surgery can improve outcomes for people with head and neck cancer that has returned or persisted. About 180 participants with PD-L1 positive tumors will receive either standard surger…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Could skipping chemo after head and neck cancer surgery be just as effective?
Disease control Recruiting nowThis study looks at whether adding the chemotherapy drug cisplatin to standard radiation therapy helps prevent head and neck cancer from coming back after surgery. About 189 people with stage III or IVA squamous cell carcinoma of the head and neck will take part. Researchers will…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 27, 2026 23:06 UTC
-
New drug aims to prevent painful mouth sores in head and neck cancer treatment
Symptom relief Recruiting nowThis study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside usual mouth rinses and pain medications. The goal is to impro…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 15, 2026 18:57 UTC
-
Mayo clinic hunts for throat cancer clues in blood and saliva
Knowledge-focused Recruiting nowThis study aims to find biological markers (biomarkers) that can show if a person has HPV-related throat cancer. Researchers will collect blood, tissue, and saliva samples from 560 people with and without the disease. The goal is to improve how doctors diagnose and predict outcom…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:51 UTC
-
New imaging study reveals hidden vascular damage from radiation therapy
Knowledge-focused Recruiting nowThis study looks at how radiation therapy for head and neck cancers affects blood vessels in the neck. Researchers will use special PET/CT scans to compare two imaging methods. About 20 adults with certain head and neck cancers will take part. The goal is to better understand rad…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:29 UTC